ANNX

Rating neutralAI MemoPost-earnings T+3

Annexon

As of 2026-08-20/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-20 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Tanruprubart BLA submission expected in Q4 2026 • 2026-11-18

Base target: $6 / p=50% prob

Biggest risk

The thesis remains binary and low-coverage. FORWARD evidence is early and open-label, ARCHER II results are unproven, and regulatory acceptance of the GBS package is not assured. No reliable post-print analyst revisions, target changes, or consensus surprise data are available in the packet.

Invalidation

Break below $3 or thesis failure.

What would change my mind?

ANNX now has multiple dated potential value inflections: a Q4 2026 GBS BLA path, an EMA review, ARCHER II data, and ANX1502 proof-of-concept results. The company also reports encouraging early FORWARD outcomes and improved financing flexibility [#SEC-8K-2026-08-12] [#EARNINGS-TRANSCRIPT-2026Q2].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-20

Base target

p=50%

Bull target

$11

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Runway extension reduces near-term financing pressure
ANNX now has multiple dated potential value inflections: a Q4 2026 GBS BLA path, an EMA review, ARCHER II data, and ANX1502 proof-of-concept results.
The company also reports encouraging early FORWARD outcomes and improved financing flexibility [#SEC-8K-2026-08-12] [#EARNINGS-TRANSCRIPT-2026Q2].

BearKey bullets

ANX1502 proof-of-concept results may not establish clinical or commercial viability.
ARCHER II Month 15 or Month 24 clinical failure or delay.
Analyst revisions, earnings surprise versus consensus, and post-release attribution of the market reaction are unavailable.

WatchKey bullets

Tanruprubart BLA submission expected in Q4 2026

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $6 (p=50%)

Target spread vs base: +77% / -52%

Scenario probabilities

Bull Target: $11 (p=25%)Base Target: $6 (p=50%)Bear Target: $3 (p=25%)

Commentary

The earnings follow-up is cautiously constructive because the company reaffirmed several dated clinical and regulatory milestones and extended runway into 2028. Reported Q2 results cannot be classified as a beat or miss from the available evidence, and analyst revisions, target changes, and trusted attribution of the post-release price reaction are unavailable. Social coverage is absent, so confidence remains moderate despite the stronger deterministic signal.

As of 2026-08-20 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Runway extension reduces near-term financing pressure

Scenarios

Bull Target (Scenario probability)

$11 / p=25% prob

Base Target (Scenario probability)

$6 / p=50% prob

Bear Target (Scenario probability)

$3 / p=25% prob

Analysis 2026-08-20 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.60

Social Sentiment (7d)

0.50

Events

Other notable items detected

EVENT2026-11-18
Tanruprubart BLA submission expected in Q4 2026
The company reports early positive outcomes from the FORWARD GBS study, an EU application under review, and a planned U.S. BLA submission in Q4 2026. The regulatory path remains consequential and execution-dependent [#SEC-8K-2026-08-12] [#EARNINGS-TRANSCRIPT-2026Q2].
Prob 60.00% • Move 35.00% • Priced-in 40.00%
EVENT2026-11-18
ARCHER II Month 15 geographic-atrophy endpoint
ARCHER II remains on track for a Month 15 primary endpoint in Q4 2026. Annexon added a Month 24 dual-primary strategy, with final trial completion expected in Q3 2027; this creates substantial upside but leaves binary clinical risk [#SEC-8K-2026-08-12].
Prob 50.00% • Move 60.00% • Priced-in 35.00%
EVENT2026-11-18
ANX1502 proof-of-concept update
Dosing is complete in the CAD proof-of-concept study, with a fall 2026 update expected on pharmacokinetic, pharmacodynamic, complement, and bilirubin-marker results [#SEC-8K-2026-08-12].
Prob 45.00% • Move 20.00% • Priced-in 20.00%

Short-term Catalysts

Next few weeks

Runway extension reduces near-term financing pressure
2026-11-18
Annexon entered a credit facility of up to $200 million, initially drawing $50 million, and says the transaction extends anticipated runway into 2028. This supports near-term execution, though future financing and dilution risk remain relevant for a development-stage biotech [#SEC-8K-2026-08-12].
Prob 75% • Move 10% • Priced-in 60%

Long-term Catalysts

Months to a year

No long-term catalysts

Risks

ANX1502 proof-of-concept results may not establish clinical or commercial viability.
ARCHER II Month 15 or Month 24 clinical failure or delay.
Analyst revisions, earnings surprise versus consensus, and post-release attribution of the market reaction are unavailable.
Development costs and future capital needs may create dilution or financing risk.
Early FORWARD results may not generalize to broader GBS populations.
FDA or EMA requests for additional evidence or delayed regulatory decisions for tanruprubart.
Low coverage and loose peer comparability increase valuation uncertainty.

Peers

Symbol	Summary
CLYM	Same-sector, similar-market-cap biotech comparator from the packet; useful for small-cap development and event-risk framing, but not established as a direct mechanism or indication peer.
DSGN	Same-sector, similar-market-cap development-stage comparator; relevant mainly for clinical-readout volatility rather than direct operating comparability.
GERN	Same-sector, similar-market-cap biotech comparator; useful as a loose capital-markets and pipeline-risk reference.
JANX	Same-sector, similar-market-cap therapeutics comparator; relevant to development-stage valuation dispersion, with limited direct comparability.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-20

Loading AI feed…

Symbol

Summary

CLYM

Same-sector, similar-market-cap biotech comparator from the packet; useful for small-cap development and event-risk framing, but not established as a direct mechanism or indication peer.

DSGN

Same-sector, similar-market-cap development-stage comparator; relevant mainly for clinical-readout volatility rather than direct operating comparability.

GERN

Same-sector, similar-market-cap biotech comparator; useful as a loose capital-markets and pipeline-risk reference.

JANX

Same-sector, similar-market-cap therapeutics comparator; relevant to development-stage valuation dispersion, with limited direct comparability.